Background
Methods
Reagents and cell culture
Knockdown of KIAA1199 by shRNA-mediated RNA interference
Western blot analysis
mRNA analysis
Cell motility and migration assay
Cell proliferation and apoptosis assay
Tumor growth assay
Immunohistochemical analysis
Quantitative proteomic analysis
Statistical analysis
Ethics statement
Results
Expression of KIAA1199 in breast cancer specimens
Reporter | Cancer type | Breast samples | Tumor samples | t-Test | p-Value | Fold change |
---|---|---|---|---|---|---|
TCGAa
| Invasive Breast Carcinoma | 61 | 76 | 14.019 | 3.39E-28 | 9.094 |
TCGA | Invasive Ductal Breast Carcinoma | 61 | 392 | 19.021 | 1.71E-36 | 8.233 |
TCGA | Invasive Lobular Breast Carcinoma | 61 | 36 | 8.501 | 7.32-12 | 5.527 |
Gluck et al.
b
| Invasive Breast Carcinoma | 4 | 154 | 9.603 | 2.48E-7 | 2.926 |
Richardson et al.
c
| Ductal Breast Carcinoma | 7 | 40 | 6.564 | 1.06E-6 | 4.125 |
Core | Breast cancer type | Sex | Age | Tissue area | Threshold (%) | Log2*
|
---|---|---|---|---|---|---|
a1 | Phyllodes Tumor | F | 45 | 271599 | 0.15 | −2.72 |
b1 | Non-neoplastic | F | 45 | 254568 | 0.12 | −3.04 |
a2 | Infiltrating Ductal Carcinoma | F | 58 | 332807 | 1 | 0 |
b2 | Non-neoplastic | F | 58 | 191591 | 0 | −9.32 |
a3 | Invasive Lobular Carcinoma | F | 51 | 326860 | 3.12 | 1.64 |
b3 | Non-neoplastic | F | 51 | 247173 | 0.64 | −0.65 |
a4 | Infiltrating Ductal Carcinoma | F | 66 | 332029 | 18.21 | 4.19 |
b4 | Non-neoplastic | F | 66 | 143861 | 0.01 | −6.68 |
a5 | Infiltrating Ductal Carcinoma | F | 54 | 373279 | 0.54 | −0.88 |
b5 | Non-neoplastic | F | 54 | 277105 | 0.16 | −2.65 |
c1 | Infiltrating Ductal Carcinoma | F | 55 | 340233 | 8.12 | 3.02 |
d1 | Non-neoplastic | F | 55 | 83421 | 0 | −8.7 |
c2 | Infiltrating Ductal Carcinoma | F | 63 | 273915 | 1.44 | 0.53 |
d2 | Non-neoplastic | F | 63 | 270038 | 2.87 | 1.52 |
c3 | Atypical Medullary Carcinoma | M | 72 | 306756 | 0.02 | −5.88 |
d3 | Non-neoplastic | M | 72 | 195427 | 0.07 | −3.84 |
c4 | Infiltrating Ductal Carcinoma | F | 64 | 358767 | 23.08 | 4.53 |
d4 | Non-neoplastic | F | 64 | 215357 | 0 | −11.07 |
c5 | Atypical Medullary Carcinoma | F | 49 | 253762 | 0.02 | −5.45 |
d5 | Non-neoplastic | F | 49 | 304971 | 0.18 | −2.51 |
e1 | Infiltrating Ductal Carcinoma | F | 38 | 355620 | 7.01 | 2.81 |
f1 | Non-neoplastic | F | 38 | 260062 | 0.1 | −3.38 |
e2 | Infiltrating Ductal Carcinoma | F | 41 | 381085 | 0.87 | −0.2 |
f2 | Non-neoplastic | F | 41 | 30471 | 0.19 | −2.37 |
Knockdown of KIAA1199 in breast cancer cell lines
KIAA1199 knockdown inhibits in vitrocell proliferation and migration and enhances apoptosis
KIAA1199 knockdown inhibits tumor incidence/growth and cell proliferation
Quantitative proteomic analysis of MDA-MB-231-ShNC and MDA-MB-231-ShB cells
Functional categories | Protein names |
---|---|
Apoptosis [n = 7, 8%] | BAX (1.50, 4.53E-02), FADD (1.63, 2.17E-02), DIO-1 (25.39, 5.91E-55), AKAP95 (2.19, 4.12E-06), PGRMC1 (0.62, 0.01), GNAS (0.53, 3.30E-4), TFG (0.59, 6.19E-03) |
DNA repair and cell cycle [n = 8, 9%] | SMC1A (1.62, 4.66E-02), ANAPC10 (0.11, 4.30E-44), PPP1CB (0.64, 3.35E-2), PPP2R1A (0.46, 4.1E-06), CRABP2 (4.24, 5.69E-20), C10orf78 (2.21, 3.14E-06), NXN (0.60, 0.01), TK1 (0.61, 8.50E-03) |
Gene regulation, RNA expression, mRNA splicing, and protein synthesis and transport [n = 30, 33%] | RBBP4 (1.68, 2.18E-02), WDR5 (8.98, 2.37E-24), ZNF259 (1.52, 4.84E-02), SFRS5 (1.60, 2.16E-02), STAU1 (1.63, 1.30E-02), RPL37A (1.53, 0.04), EIF2S2 (1.57, 0.03), TMED2 (1.56, 2.98E-02), KIAA0521 (1.77, 2.00E-03), SRP14 (2.28, 3.14E-05), HNRPA1L-2 (7.61, 7.77E-38), SRP72 (0.26, 2.07E-17), RGPD5 (0.36, 5.44E-10), PQBP1 (0.44, 2.57E-06), TERF2IP (0.47, 8.95E-06), SEC23B (0.49, 4.08E-05), SUPT5H (0.51, 1.78E-04), FUBP1 (0.52, 2.79E-04), PPP1R14B (0.52, 2.79E04), CPSF3 (0.57, 2.75E-03), HMGA1 (0.58, 5.70E-03), RPS15 (0.60, 6.49E-03), KIAA1150 (0.60, 2.75E-03), ELAC2 (0.61, 9.85E-03), FARSA (0.62, 0.01), SNRNP70 (0.63, 0.02), BASP1 (0.64, 0.03), KIAA0324 (0.65, 0.04), PRPF4 (0.65, 0.48), MAGED2 (0.65, 0.02) |
Metabolism [n = 11, 12%] | ATP5C1 (1.62, 0.02), PGLS (0.59, 4.34E-03), PGAM4 (0.38, 6.95E-10), ACAA1 (0.03, 6.80E-104), ACOT2 (0.37, 8.07E-10), USMG5 (1.55, 3.69E-02), GCDH (1.69, 5.90E-03), ALDH9A1 (6,60, 5.67E-33), RRM2 (0.47, 1.18E-06), AK1 (0.49, 1.44E-10), VAT1 (0.57, 3.66E-03) |
Cytoskeleton, cell adhesion and cell motility [n = 14, 15%] | S100A11 (1.82, 1.13E-03), TACC3 (0.58, 4.54E-03), WASL (0.10, 3.76E-48), PPP1R9B (0.25, 1.40E-18), TNXB (0.09, 2.43E-52), SEPT9 (0.57, 1.76E-03), NCKIPSD (1.54, 3.95E-02), ACTR3 (11.59, 1.39E-51), LUM (0.07, 7.40E-59), KIAA0345 (0.23, 6.31E20), THBS1 (0.41, 5.28E-09), ARHGEF2 (0.43, 8.89E-07), ZYX (0.43, 1E-06), SDCBP (0.53, 5.15E-04) |
Ubiquitin proteasome pathway [n = 6, 7%] | UBE2V1 (0.63, 2.59E-02), ZFP91 (0.53, 3.87E-04), UBE2C (0.49, 3.04E-05), UBE2L3 (0.55, 3.88E-04), UBE2K (0.56, 1.61E-03), KIAA0439 (0.65, 0.03) |
Oxidative Stress [n = 1, 1%] | DJ-1 (2.01, 7.10E-04) |
Others [n = 14, 15%] | ACP1 (1.52, 4.72E-02), CYR61 (1.56, 3.49E-02), HBA1 (0.02, 7.30E-102), LTF (0.02, 3.80E-102), HBE1 (0.11, 2.89E-42), ALB (0.13, 2.21E-38), CHCHD2 (0.37, 3.94E-10), C19orf43 (0.39, 6,69E-09), CCDC86 (0.40, 4.27E-08), COX17 (0.45, 5.23E-06), C1orf122 (0.46, 6.59E-06), ZC3H18 (0.46, 8.95E-06), TXLNA (0.49, 9.02E-06), C11orf84 (0.52, 3.18E-05) |